Wednesday, August 05, 2009 11:15:36 AM
Aug 5, 2009, 10:59 a.m. EST
BOSTON (MarketWatch) -- Drug stocks slipped in early action Wednesday as shares of Onyx Pharmaceuticals slid on news that it plans to hold two public offerings.
Onyx said late Tuesday that it plans to offer 4 million common shares and $200 million in convertible senior notes due in 2016. The offerings are subject to market conditions.
Also late Tuesday, Onyx reported higher second-quarter earnings of 16 cents a share, compared with 8 cents in the 2008 period.
Revenue rose to $60 million, up from $45 million, due primarily to increased sales of its oncology drug Nexavar, which is co-marketed with Bayer AG.
Early Wednesday, analysts at Caris reportedly cut their rating on Onyx to above average from buy.
Shares of Inovio Biomedical /quotes/comstock/14*!ino/quotes/nls/ino (INO 2.66, +0.51, +23.73%) shot up 20% to $2.58.
Late Tuesday, Inovio reported positive results from a study for its experimental DNA-based vaccine in the treatment of prostate cancer.
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM